| Literature DB >> 29730191 |
Giuseppe La Regina1, Ruoli Bai2, Antonio Coluccia1, Valentina Naccarato1, Valeria Famiglini1, Marianna Nalli1, Domiziana Masci1, Annalisa Verrico3, Paola Rovella3, Carmela Mazzoccoli4, Eleonora Da Pozzo5, Chiara Cavallini5, Claudia Martini5, Stefania Vultaggio6, Giulio Dondio7, Mario Varasi6, Ciro Mercurio6, Ernest Hamel2, Patrizia Lavia3, Romano Silvestri8.
Abstract
We designed new 3-arylthio- and 3-aroyl-1H-indole derivatives 3-22 bearing a heterocyclic ring at position 5, 6 or 7 of the indole nucleus. The 6- and 7-heterocyclyl-1H-indoles showed potent inhibition of tubulin polymerization, binding of colchicine to tubulin and growth of MCF-7 cancer cells. Compounds 13 and 19 inhibited a panel of cancer cells and the NCI/ADR-RES multidrug resistant cell line at low nanomolar concentrations. Compound 13 at 50 nM induced 77% G2/M in HeLa cells, and at 20 nM caused 50% stable arrest of mitosis. As an inhibitor of HepG2 cells (IC50 = 20 nM), 13 was 4-fold superior to 19. Compound 13 was a potent inhibitor of the human U87MG glioblastoma cells at nanomolar concentrations, being nearly one order of magnitude superior to previously reported arylthioindoles. The present results highlight 13 as a robust scaffold for the design of new anticancer agents.Entities:
Keywords: Cancer cell; Indole; Inhibitor; Microtubule; Tubulin
Mesh:
Substances:
Year: 2018 PMID: 29730191 DOI: 10.1016/j.ejmech.2018.04.042
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514